Literature DB >> 83150

Bleomycin lung damage: the pathology and nature of the lesion.

A W Jones.   

Abstract

The pathology of two cases of pulmonary damage due to bleomycin is described. The drug damages the alveolar walls. A sequence of pathological changes could be traced commencing with oedema, intra-alveolar fibrin and haemorrhage, followed by type II pneumocyte hyperplasia associated with bronchial epithelial squamous metaplasia. This led to intra-alveolar and alveolar wall collagen formation producing diffuse interstitial fibrosis with microcyst formation associated with cuboidalization of the epithelium. These changes are similar to those seen in experimental bleomycin damage in mice, where it has been shown that the changes are the result of vascular damage and type I pneumocyte necrosis. It is inferred that human diffuse alveolar damage develops in the same way.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 83150

Source DB:  PubMed          Journal:  Br J Dis Chest        ISSN: 0007-0971


  13 in total

1.  Pulmonary veno-occlusive disease after chemotherapy.

Authors:  B K Knight; A G Rose
Journal:  Thorax       Date:  1985-11       Impact factor: 9.139

2.  Development of acute lung injury after the combination of intravenous bleomycin and exposure to hyperoxia in rats.

Authors:  J G Hay; P L Haslam; A Dewar; B Addis; M Turner-Warwick; G J Laurent
Journal:  Thorax       Date:  1987-05       Impact factor: 9.139

3.  Augmentation of fibroblast proliferation by bleomycin.

Authors:  P L Moseley; C Hemken; G W Hunninghake
Journal:  J Clin Invest       Date:  1986-11       Impact factor: 14.808

Review 4.  Lung damage from cytotoxic drugs.

Authors:  C H Collis
Journal:  Cancer Chemother Pharmacol       Date:  1980       Impact factor: 3.333

5.  A Lipidomics Approach to Identifying Key Lipid Species Involved in VEGF-Inhibitor Mediated Attenuation of Bleomycin-Induced Pulmonary Fibrosis.

Authors:  Yogesh M Kulkarni; Sucharita Dutta; Anand Krishnan V Iyer; Clayton A Wright; Vani Ramesh; Vivek Kaushik; Oliver John Semmes; Neelam Azad
Journal:  Proteomics Clin Appl       Date:  2018-01-19       Impact factor: 3.494

6.  Experimental bleomycin lung in mice. A contribution to the pathogenesis of pulmonary fibrosis.

Authors:  E Fasske; K Morgenroth
Journal:  Lung       Date:  1983       Impact factor: 2.584

Review 7.  The correlation of lung structure with function.

Authors:  N Berend
Journal:  Lung       Date:  1982       Impact factor: 2.584

8.  Cardiopulmonary and histological characterization of an acute rat lung injury model demonstrating safety of mesenchymal stromal cell infusion.

Authors:  Rudolf K Braun; Jill M Koch; Timothy A Hacker; David Pegelow; Jaehyup Kim; Amish N Raval; Eric G Schmuck; Denise J Schwahn; Derek J Hei; John M Centanni; Marlowe Eldridge; Peiman Hematti
Journal:  Cytotherapy       Date:  2016-04       Impact factor: 5.414

9.  Bleomycin lung: the effect of different chemotherapeutic regimens.

Authors:  R A Chisholm; A K Dixon; M V Williams; R T Oliver
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

10.  IL-17 producing gammadelta T cells are required for a controlled inflammatory response after bleomycin-induced lung injury.

Authors:  Ruedi K Braun; Christina Ferrick; Paul Neubauer; Michael Sjoding; Anja Sterner-Kock; Martin Kock; Lei Putney; David A Ferrick; Dallas M Hyde; Robert B Love
Journal:  Inflammation       Date:  2008-03-13       Impact factor: 4.092

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.